Bioceltix start-up lands 17 million PLN for pets stem cell treatment.

According to the National Pet Owners Survey, conducted by the American Pet Products Association, 85 million families in the United States own a pet. As the number of their owners grows, so does the demand for high-quality veterinary services. In particular, biological drugs are gaining in importance. The Polish start-up has already obtained approximately 17 million PLN in funding for the development of drugs for companion animals, the active substances of which are mesenchymal stem cells derived from adipose tissue.

The technology of the Polish start-up may revolutionize the biological medicines market in veterinary medicine. It allows for serial production of a drug based on stem cells, thanks to which the drugs will be available immediately and ready to be administered to the patient immediately after thawing. This will make drugs much more readily available.


Our privacy policy